These results are consistent with the model in which quercetin inhibits tumor growth by suppressing the expression of AXL and activation of STAT3 in NSCLC cells, while brigatinib inhibits tumor growth by suppressing pEGFR in NSCLC cells (Figure 4F). Here, AXL is linked to non-small cell lung carcinoma.